Lonza announced that Richard Ridinger, CEO, has decided to retire from the company after seven successful years. His successor as CEO as of 1 March 2019 will be Marc Funk, currently Chief Operating Officer of the Pharma & Biotech division. To ensure a seamless transition of leadership, Richard Ridinger will remain with the company until the end of April and will then be available to Lonza in an advisory capacity until the end of 2019.